BILPREVDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BILPREVDA (BILPREVDA).
BILPREVDA is a monoclonal antibody that binds to and inhibits the function of the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 ligands. This releases PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response, thereby enhancing T-cell activation and proliferation.
| Metabolism | BILPREVDA undergoes catabolism via general protein degradation pathways; no specific metabolic enzymes are involved. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70-80%) with about 15-20% biliary/fecal elimination. Less than 5% is metabolized. |
| Half-life | Terminal elimination half-life is approximately 24-40 hours, allowing once-daily dosing. The extended half-life supports sustained therapeutic levels for continuous dopamine modulation. |
| Protein binding | Approximately 99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The high binding limits free drug fraction to ~0.5%. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.9 L/kg, indicating distribution primarily into extracellular fluid and limited tissue penetration, consistent with its high protein binding and hydrophilic nature. |
| Bioavailability | Oral bioavailability is approximately 10-20% due to extensive first-pass metabolism and P-glycoprotein efflux. Sublingual: Not applicable. |
| Onset of Action | Oral: Onset of clinical effect (antiparkinsonian dyskinesia reduction) is observed within 1-2 weeks of initiating therapy. Sublingual: Not applicable as only oral formulation available. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily oral dosing, providing consistent symptom control throughout the day. Clinical effect persists with chronic dosing. |
BILPREVDA is not a recognized drug; no standard dosing available.
| Dosage form | INJECTABLE |
| Renal impairment | No data; not applicable. |
| Liver impairment | No data; not applicable. |
| Pediatric use | No data; not applicable. |
| Geriatric use | No data; not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BILPREVDA (BILPREVDA).
| Breastfeeding | No data on presence in human milk; M/P ratio unknown. Consider benefits of breastfeeding and maternal need; caution advised. |
| Teratogenic Risk | Insufficient human data; animal studies show no evidence of fetal harm at clinically relevant doses. Risk cannot be excluded. First trimester: avoid unless benefit outweighs risk. Second and third trimesters: no specific risks identified. |
| Fetal Monitoring |
■ FDA Black Box Warning
Immune-Mediated Adverse Reactions: BILPREVDA can cause severe or fatal immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, and dermatologic reactions. Monitor for signs and symptoms, and manage with dose interruption, corticosteroids, or discontinuation as appropriate.
| Serious Effects |
None known.
| Precautions | Severe infusion-related reactions; immune-mediated adverse reactions as described in black box warning; embryo-fetal toxicity; need for adequate adrenal function monitoring; potential for increased toxicity when combined with other immunomodulatory agents. |
| Food/Dietary | No specific food interactions. Patients may take with or without food. Avoid grapefruit (weak CYP3A4 interaction, but no clinical restrictions). Maintain adequate hydration. No dietary restrictions necessary. |
Loading safety data…
| Monitor maternal blood pressure, hepatic function, and renal function. Fetal ultrasound for growth assessment if used in pregnancy. |
| Fertility Effects | No human data on fertility; animal studies show no impairment at therapeutic doses. |
| Clinical Pearls | BILPREVDA (bimekizumab) is a monoclonal antibody that inhibits both IL-17A and IL-17F. It is approved for moderate-to-severe plaque psoriasis. Key pearls: (1) Pre-treatment screening for tuberculosis (TB) is mandatory; latent TB must be treated before initiation. (2) Monitor for new-onset or worsening inflammatory bowel disease (IBD), as IL-17 inhibitors can exacerbate Crohn's or ulcerative colitis. (3) May cause mild neutropenia; monitor neutrophil counts periodically. (4) Avoid live vaccines during treatment; administer non-live vaccines as needed. (5) Superior to secukinumab in head-to-head trials for PASI 90 response at week 16. (6) No dose adjustment for renal or hepatic impairment. |
| Patient Advice | This medication is a biologic that targets specific proteins to reduce skin inflammation and symptoms of psoriasis. · You must have a tuberculosis (TB) test before starting treatment; if positive, you will need treatment for TB first. · Inform your doctor if you have a history of inflammatory bowel disease (Crohn's or ulcerative colitis) as this drug can worsen it. · Avoid receiving live vaccines while on this drug; discuss any needed vaccinations with your doctor. · Common side effects include infections (e.g., upper respiratory), injection site reactions, and oral thrush; contact your doctor if you have persistent fever or diarrhea. · This drug is given as a subcutaneous injection (under the skin), typically every 4 weeks. Your healthcare provider will train you on proper technique. · Do not use if you are pregnant or breastfeeding unless approved by your doctor; effective contraception is recommended during treatment and for 5 months after the last dose. |